This is a working overview of Chromatographic purity, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-12. Anything still debated is marked as such rather than presented as settled.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Field-flow fractionation, abbreviated FFF, is a separation technique invented by J. Calvin Giddings. The technique is based on separation of colloidal or high molecular weight substances in liquid solutions, flowing through the separation platform, which does not have a stationary phase. It is similar to liquid chromatography, as it works on dilute solutions or suspensions of the solute, carried by a flowing eluent. Separation is achieved by applying a field (hydraulic, centrifugal, thermal, electric, magnetic, gravitational, ...) or cross-flow, perpendicular to the direction of transport of the sample, which is pumped through a long and narrow laminar channel. The field exerts a force on the sample components, concentrating them towards one of the channel walls, which is called accumulation wall. The force interacts with a property of the sample, thereby the separation occurs, in other words, the components show differing "mobilities" under the force exerted by the crossing field. As an example, for the hydraulic, or cross-flow FFF method, the property driving separation is the translational diffusion coefficient or the hydrodynamic size. For a thermal field (heating one wall and cooling the other), it is the ratio of the thermal and the translational diffusion coefficient.
Deployment of such agents began to accelerate in late 2023 after OpenAI's "function-calling" API was made available, and especially after Anthropic's late 2024 introduction of Model Context Protocol (MCP), a standardised way for LLM agents to gain contextual awareness, and to act on the world by calling various external tools. The term "agentic" only began to be used with any frequency in 2024, popularised in part by researcher Andrew Ng.
Competitive inhibitors can bind to E, but not to ES. Competitive inhibition increases Km (i.e., the inhibitor interferes with substrate binding), but does not affect Vmax (the inhibitor does not hamper catalysis in ES because it cannot bind to ES). Uncompetitive inhibitors bind to ES. Uncompetitive inhibition decreases both Km and Vmax. The inhibitor affects substrate binding by increasing the enzyme's affinity for the substrate (decreasing Km) as well as hampering catalysis (decreases Vmax). Non-competitive inhibitors have identical affinities for E and ES (Ki = Ki'). Non-competitive inhibition does not change Km (i.e., it does not affect substrate binding) but decreases Vmax (i.e., inhibitor binding hampers catalysis). Mixed-type inhibitors bind to both E and ES, but their affinities for these two forms of the enzyme are different (Ki ≠ Ki'). Thus, mixed-type inhibitors affect substrate binding (increase or decrease Km) and hamper catalysis in the ES complex (decrease Vmax). When an enzyme has multiple substrates, inhibitors can show different types of inhibition depending on which substrate is considered. This results from the active site containing two different binding sites within the active site, one for each substrate. For example, an inhibitor might compete with substrate A for the first binding site, but be a non-competitive inhibitor with respect to substrate B in the second binding site. Traditionally reversible enzyme inhibitors have been classified as competitive, uncompetitive, or non-competitive, according to their effects on Km and Vmax.
The first Este dukes ruled well and the city achieved an economic and cultural peak: Borso's successor Duke Ercole I had the city of Modena rebuilt according to plans designed by Biagio Rossetti, his successors were patrons of artists like Titian and Ludovico Ariosto. In the War of the League of Cambrai from 1508, troops from Modena fought in Papal service against the Republic of Venice. Upon the death of Duke Alfonso II in 1597, the ducal line became extinct. The Este lands were bequeathed to Alfonso's cousin Cesare d'Este; however, the succession was not acknowledged by Pope Clement VIII and Ferrara was finally seized by the Papacy. Cesare was able to retain Modena and Reggio as Imperial fiefs. In the 1628 War of the Mantuan Succession, the dukes of Modena sided with Habsburg Spain and in turn received the town of Correggio from the hands of Emperor Ferdinand II. During the War of the Spanish Succession, Duke Rinaldo was ousted by French troops under Louis Joseph, Duke of Vendôme, he could not return until 1707. In 1711 the small Duchy of Mirandola was absorbed by the Este. His successor Francesco III backed France in the 1740 War of the Austrian Succession and was expelled by Habsburg forces, but his duchy was restored by the 1748 Treaty of Aix-la-Chapelle. In 1796 Modena was again occupied by a French army under Napoleon, who deposed Duke Ercole III and created the Cispadane Republic out of his territory.
Sources: en.wikipedia.org
=== Oxidative damage === In aerobic organisms the energy needed to fuel biological functions is produced in the mitochondria via the electron transport chain. Reactive oxygen species (ROS) with the potential to cause cellular damage are produced along with the release of energy. ROS can damage lipids, DNA, RNA, and proteins, which, in theory, contributes to the physiology of aging. ROS are produced as a normal product of cellular metabolism. In particular, one major contributor to oxidative damage is hydrogen peroxide (H2O2), which is converted from superoxide that leaks from the mitochondria. Catalase and superoxide dismutase ameliorate the damaging effects of hydrogen peroxide and superoxide, respectively, by converting these compounds into oxygen and hydrogen peroxide (which is later converted to water), resulting in the production of benign molecules. However, this conversion is not 100% efficient, and residual peroxides persist in the cell. While ROS are produced as a product of normal cellular functioning, excessive amounts can cause deleterious effects.
Powder cocaine (cocaine hydrochloride) must be heated to a high temperature to be smoked (about 197 °C), and considerable decomposition/burning occurs at these high temperatures. This effectively destroys some of the cocaine and yields a sharp, acrid, and foul-tasting smoke. Cocaine base/crack can be smoked because it vaporizes with little or no decomposition at 98 °C (208 °F).
In 2004, Eurogentec opened its new production laboratories (Oligonucleotides and peptides synthesis) in the Liege Science PARK (Belgium). This intelligent building is also ecological: the building is equipped with a home automation system (lighting without switch) and the heating is produced from a condensation boiler allowing energy savings. From 2000 to 2008 Eurogentec intensified its services and signed agreements with several companies like Cepheid, Epoch Biosciences, Exiqon, Delphi, In Cell Art. 2007: In order to fully meet the Oligonucleotide in vitro diagnostics stringent manufacturing requirements, Eurogentec expanded its current GMP facility in Liège. In 2008, Eurogentec received ISO 13485 Certification for the production and sales of In Vitro Diagnostics (IVD) oligonucleotides in Liège. Two years after EGT NA also received ISO 13485 certification for the Oligonucleotide diagnostics manufacturing.
(i) Opium, opiates, derivatives of opium and opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation. Such a term does not include the isoquinoline alkaloids of opium. (ii) Poppy straw and concentrate of poppy straw. (iii) Coca leaves, except coca leaves and extracts of coca leaves from which cocaine, ecgonine and derivatives of ecgonine or their salts have been removed. (iv) Cocaine, its salts, optical and geometric isomers, and salts of isomers. (v) Ecgonine, its derivatives, their salts, isomers, and salts of isomers. (vi) Any compound, mixture, or preparation which contains any quantity of any of the substances referred to in paragraphs (b)(31)(i) through (v) of this section.
== Discovery and development == Opioid drugs are known to cause opioid-induced constipation (OIC) by inhibiting gastric emptying and decreasing peristaltic waves leading to delayed absorption of medications and more water absorption from the feces. That can result in hard and dry stool and constipation for some patients. OIC is one of the most common adverse effects caused by opioids, so the discovery of PAMORAs can prevent the effects that often compromise pain management. Methylnaltrexone bromide was the first medication in the drug class approved by the FDA. It was discovered in 1979 by Leon Goldberg, a pharmacologist at the University of Chicago. Having witnessed the suffering of a dying friend with OIC, Goldberg tested various derivatives of naltrexone, a drug known to block the effects of opioids. His objective was to find a drug that could not pass the blood brain barrier, without affecting the analgesic effects of the opioids. After Goldberg died, his colleagues at the university continued to develop the compound. It was approved by the FDA in April 2008, originally for OIC in adult patients with advanced illness and later in adult patients with chronic noncancer pain. In the late 1970s, Dennis M. Zimmerman and his co-workers from Lilly Research Laboratories, Indiana, did research on structural concepts for narcotic antagonists defined in a 4-phenylpiperidine series. They reported N-methyl-trans-3,4-dimethyl-4-phenylpiperidine to be pure opioid receptor antagonist with a new pharmacophore.
Sources: en.wikipedia.org
In the average person, the diaphragm should be intersected by the 5th to 7th anterior ribs at the mid-clavicular line, and 9 to 10 posterior ribs should be viewable on a normal PA inspiratory film. An increase in the number of viewable ribs implies hyperinflation, as can occur, for example, with obstructive lung disease or foreign body aspiration. A decrease implies hypoventilation, as can occur with restrictive lung disease, pleural effusions or atelectasis. Underexpansion can also cause interstitial markings due to parenchymal crowding, which can mimic the appearance of interstitial lung disease. Enlargement of the right descending pulmonary artery can indirectly reflect changes of pulmonary hypertension, with a size greater than 16 mm abnormal in men and 15 mm in women. Appropriate penetration of the film can be assessed by faint visualization of the thoracic spines and lung markings behind the heart. The right diaphragm is usually higher than the left, with the liver being situated beneath it in the abdomen. The minor fissure can sometimes be seen on the right as a thin horizontal line at the level of the fifth or sixth rib. Splaying of the carina can also suggest a tumor or process in the middle mediastinum or enlargement of the left atrium, with a normal angle of approximately 60 degrees. The right paratracheal stripe is also important to assess, as it can reflect a process in the posterior mediastinum, in particular the spine or paraspinal soft tissues; normally it should measure 3 mm or less.
Recurrences of the MFS at the site of surgery have developed in 16% to 57% of patients with a significant proportion (25%–52%) recurring multiple times. In one study, recurrences developed between 2 and 82 months (median 53 months) following primary surgery and metastatic disease developed in 23% of patients within 2 to 77 months (median 10 months) following primary surgery. Recurrent tumors tend to be more aggressive and have a much greater tendency to metastasize than primary MFS tumors. In one study, metastatic disease was detected in 23% of patients and occurred at a median of 10 months (range, 2–77 months) after resection of the primary tumor. In a review of multiple studies, the risk of developing metastases for lower grade MFS (defined in the following section) was <5% and for higher grade tumors was 25–30%. MFS metastasize most commonly to the lungs, bone, and lymph-nodes. Individuals with the epithelioid variant of FBS generally present with a tumor in the limbs; the tumors tend to be somewhat larger, more aggressive, and more likely to metastasize than the tumors in non-variant cases. At least 50% of patients with this variant have developed metastases.
Metabolic myopathies are myopathies that result from defects in biochemical metabolism that primarily affect muscle. They are generally genetic defects (inborn errors of metabolism) that interfere with the ability to create energy, causing a low ATP reservoir within the muscle cell.
News of UDI was generally received calmly by the local citizenry, apart from some isolated incidents of passing cars being stoned in the black townships outside Bulawayo. A few expected dissenters were arrested, most prominently Leo Baron, Nkomo's lawyer, whose links with black Rhodesians and communists were seen by authorities as "subversive". Baron, the younger brother of the scientist Jacob Bronowski, was arrested nine minutes after UDI was made.
Arsenic trioxide exerts its toxicity primarily through the induction of oxidative stress, disruption of cellular energy production, and interference with key protein functions. One major mechanism involves the generation of reactive oxygen species (ROS), leading to oxidative modifications of cellular biomolecules, organelle damage, and ultimately cell death. Arsenic trioxide also inhibits critical cellular enzymes such as pyruvate dehydrogenase, thereby disrupting mitochondrial ATP production and cellular respiration, which results in energy failure and can trigger both necrotic and apoptotic cell death. Furthermore, it can interfere with DNA repair processes by inhibiting enzymes involved in base and nucleotide excision repair and by interacting with protein structures such as zinc fingers in repair proteins. In cardiac tissues, arsenic trioxide disrupts ion channel function, notably by blocking the hERG potassium channel and altering calcium channel activity, which can lead to prolonged QT intervals and arrhythmias, sometimes causing fatal cardiac events. The broad range of affected signaling and metabolic pathways helps explain the widespread multi-organ toxicity associated with arsenic trioxide exposure.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.